Peter Strumph
Chief Executive Officer Parvus Therapeutics
Peter Strumph has more than two decades of experience in executive leadership and technical roles supporting successful development and commercialization for 7 FDA approved novel therapies. Peter’s prior experience includes CEO at Amygdala Neurosciences, CEO at Codexis, CEO of Nile Therapeutics, SVP of Operations at Portola Pharmaceuticals, SVP of Operations at CV Therapeutics, Manager of Operations & Planning at Biogen, and an engineer at Bayer. Peter served as a Lieutenant in the US Navy. Peter earned a BAS in Systems Engineering from the University of Pennsylvania and an MBA from the Wharton School.
Seminars
Wednesday 4th March 2026
Panel Discussion: Scaling Autoimmune Cell Therapies: Overcoming Manufacturing Challenges to Improve Speed, Cost, & Reproducibility
3:30 pm
- Cell therapy place in autoimmune disease, significance and cost appropriateness
- Examining both ex vivo and in vivo approaches, highlighting the trade-offs between customized manufacturing and off-the-shelf therapies
- Evaluating current GMP-level processes which remain largely manual, creating bottlenecks in speed, cost, and reproducibility
- Discussing automated technologies, such as advanced cell sorters and bioreactors, that could streamline manufacturing
Wednesday 4th March 2026
Driving Proof-of-Mechanism & Scalable Treg Therapy Development
2:30 pm
- Translating discovery into the clinic by driving research from early discovery through preclinical validation, ensuring robust study design, regulatory alignment, and effective transition of lab findings into first-in-human studies
- Leveraging a tetramer-based assay to directly measure antigen-specific Treg populations, enabling precise proof-of-mechanism validation
- Establishing scalable GMP manufacturing processes that bridge scientific innovation and clinical application, ensuring efficient development of patient-ready therapeutics
